New! Sign up for our free email newsletter.
Science News
from research organizations

Study opens new avenue for immunotherapy drug development

Method utilizes engineered peptides to build up the body's natural response

Date:
April 19, 2024
Source:
University of Texas M. D. Anderson Cancer Center
Summary:
Researchers have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.
Share:
FULL STORY

In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.

In preclinical models of locally advanced and metastatic breast cancer, this method improved tumor control and prolonged survival, both as a monotherapy and in combination with immune checkpoint inhibitors.

"Amino acids are the building blocks of life and, when a few of them are linked together, they create a peptide. All the biological functions performed by our body are done by proteins and peptides, so our goal was to find a way to redesign these small molecules to possess the unique ability to activate our immune system," said senior author Betty Kim, M.D., Ph.D., professor of Neurosurgery.

The body's immune system is built to patrol and identify infected or diseased cells to eliminate, but cancer cells often exploit weaknesses in the immune system to avoid detection. The goal of immunotherapy is to bolster the body's natural ability to identify and destroy cancer cells. Current immune checkpoint inhibitors are antibodies designed to block specific immune signaling pathways.

The engineered peptide improves the immune system's ability to detect and destroy cancer cells in a unique way. Rather than using an external compound to initiate a response, or harvesting and modifying immune cells for cell therapies, the peptide serves as a messenger to activate specific signaling pathways in immune cells to boost their performance.

"These findings open a whole new avenue for developing immunotherapy drugs. By using designed polypeptides, we can potently activate immune signaling pathways to enhance anti-tumor responses. Additionally, since these are naturally derived agents, we anticipate the toxicity profile would be significantly better than with synthetic compounds," said co-corresponding author Wen Jiang, M.D., Ph.D., associate professor of Radiation Oncology.

This study was supported by the National Cancer Institute (CA241070) and the U.S. Department of Defense.


Story Source:

Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.


Journal Reference:

  1. DaeYong Lee, Kristin Huntoon, Yifan Wang, Minjeong Kang, Yifei Lu, Seong Dong Jeong, Todd M. Link, Thomas D. Gallup, Yaqing Qie, Xuefeng Li, Shiyan Dong, Benjamin R. Schrank, Adam J. Grippin, Abin Antony, JongHoon Ha, Mengyu Chang, Yi An, Liang Wang, Dadi Jiang, Jing Li, Albert C. Koong, John A. Tainer, Wen Jiang, Betty Y. S. Kim. Synthetic cationic helical polypeptides for the stimulation of antitumour innate immune pathways in antigen-presenting cells. Nature Biomedical Engineering, 2024; DOI: 10.1038/s41551-024-01194-7

Cite This Page:

University of Texas M. D. Anderson Cancer Center. "Study opens new avenue for immunotherapy drug development." ScienceDaily. ScienceDaily, 19 April 2024. <www.sciencedaily.com/releases/2024/04/240419131805.htm>.
University of Texas M. D. Anderson Cancer Center. (2024, April 19). Study opens new avenue for immunotherapy drug development. ScienceDaily. Retrieved May 24, 2024 from www.sciencedaily.com/releases/2024/04/240419131805.htm
University of Texas M. D. Anderson Cancer Center. "Study opens new avenue for immunotherapy drug development." ScienceDaily. www.sciencedaily.com/releases/2024/04/240419131805.htm (accessed May 24, 2024).

Explore More

from ScienceDaily

RELATED STORIES